Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq. The move – Abcam had made Aim its home since 2005 and was one of its biggest companies – was seen at the time as a blow to the Government’s efforts to champion the UK’s most innovative companies. It was also an indication that the entire London listings market was in decline with many companies since being bought out by predators and seeking higher valuations overseas. Abcam now has a new owner. Since late last year, the company has been part of Danaher Corporation, the New York-listed life sciences and diagnostics giant. Danaher paid $5.7bn (£4.6bn) in cash for Abcam, which makes and sells products, including proteins and reagents, used in medical research. It has added the business to its already extensive array of medical products and services, which range from cell production and new drugs discovery to the instruments used in clinical testing. In its former guise, Abcam had a devoted following among individual UK shareholders. Danaher has a fanbase of its own too: the world’s best fund managers....